Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Get SEC filing alerts via email and in your feed for CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

CRL

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

About CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Charles River Laboratories International, Inc. is a global provider of non-clinical drug development services, offering research models, discovery and safety assessment, and manufacturing solutions. Serving pharmaceutical, biotechnology, chemical, and academic clients worldwide, it supports early-stage drug discovery through regulatory safety testing and biologics manufacturing. The company’s integrated portfolio, scientific expertise, and global infrastructure enable efficient, cost-effective outsourcing to accelerate therapeutic innovation and reduce time to market.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

1
1
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Charles River Laboratories Reports Q1 2026 Revenue of $995.8 Million, Net Loss of $14.8 Million

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Charles River Laboratories Reports $4.02 Billion Revenue and Leadership Transition for Fiscal Year 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Charles River Laboratories Reports Revenue and Net Income Decline in Q3 Fiscal 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Charles River Laboratories Reports Slight Revenue Increase but Significant Decline in Operating Income for Q2 Fiscal 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Charles River Laboratories Reports 2.7% Revenue Decline in Q1 Fiscal 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Charles River Laboratories Reports $4.0 Billion Revenue, 1.9% Decline in Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Charles River Laboratories Reports Decline in Revenue and Net Income for Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments